RecruitingNCT07652892

Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective.

IIBSP-MAS-2025-133

Sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Enrollment

140 participants

Start Date

May 26, 2026

Study Type

OBSERVATIONAL

Conditions

Steatosis of Liver

Summary

The goal of this observational study is to determine the differences in the prevalence, characteristics and evolution of frailty between men and women diagnosed with MASLD, and to establish its relationship with clinical, functional, hormonal and social parameters.

Eligibility

Min Age: 20 YearsMax Age: 80 Years

Inclusion Criteria1

Patients will be included who are able to provide informed consent and actively participate in periodic assessments.

Exclusion Criteria5

Risky alcohol consumption:
> 30 g/day in men and > 20 g/day in women. AUDIT score: > 7 points in men, > 5 in women.
Other liver diseases (viral hepatitis, autoimmune hepatitis, etc.).
Advanced neurodegenerative diseases or severe psychiatric disorders.
Severe comorbidities or treatments that, in the researchers' judgment, may affect frailty and quality of life more than metabolic syndrome and liver disease.

Interested in this trial?

Get notified about updates and connect with the research team.